Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction.
Oral disopyramide given prophylactically following myocardial infarction has been compared with placebo in a double-blind trial using continuous-tape monoriting of the electocardiogram. It caused a significant reduction in the incidence of ventricular arrhythmias and of the various degrees of heart-block. There was a significant reduction of reinfarction during hospital stay in patients who had received disopyramide. Disopyramide appears to be a safe and effective oral therapy in the prevention of potentially serious arrhythmias following myocardial infarction.
D000284:Administration, Oral; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control*; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004206:Disopyramide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D006327:Heart Block / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications*; D010919:Placebos; D011725:Pyridines / Q000008:administration & dosage*; D014693:Ventricular Fibrillation / Q000453:epidemiology / Q000517:prevention & control
D010919:Placebos; D011725:Pyridines; D004206:Disopyramide